Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological Standardization of Artemisia Vulgaris Allergen Extract
NCT01984541Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of artemisia vulgaris pollen allergen extract in mugwort allergy, sponsored by LETI Pharma. Primary endpoint: Wheal size area. Started Mar 2014; status: completed.
02
Drugs
artemisia vulgaris pollen allergen extract
03
Conditions
mugwort allergy
Beyond the preview
Go deeper on NCT01984541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01984541.